Our Momentum Scanner Picked Up These
3 Stocks This Week
1 year performance
TERN - 1171%
NBIS - 297%
DOCN - 90%
Our Latest Momentum Top Mover
Here’s another momentum stock we called for our members (Proof here):
BE - (+433%)
Setups like the one above are exactly what our momentum scans are designed to find.
Most of the time these stocks begin showing momentum before the move becomes obvious, which is why our members see them first.
Interestingly, the stock above is one of many that stand out on a daily basis.
If you’re curious what else is appearing on our scans, you can take a look below.
Plus, we’re offering 25% off all Momentum plans as it is Federal Reserve meeting week.
Let’s Talk About Each One!
Terns Pharmaceuticals, Inc. (TERN)
1 Year Chart:
Technical Levels To Watch: UNLOCK
Risk Considerations: UNLOCK
Potential Upside: UNLOCK
Market Cap: $4B
Company Info:
Terns Pharmaceuticals is a clinical-stage biotechnology company focused on developing treatments for metabolic and liver diseases.
The company’s research pipeline targets conditions such as obesity, metabolic dysfunction-associated steatohepatitis (MASH), and related cardiometabolic disorders. These are areas where pharmaceutical companies are investing heavily due to large patient populations and growing global prevalence.
Its development efforts center on:
Developing small-molecule therapies for metabolic diseases
Advancing drug candidates targeting obesity and liver conditions
Running clinical trials to evaluate safety and effectiveness
Building a pipeline focused on high-unmet-need metabolic disorders
This is not yet a commercial pharmaceutical company. It is a research-focused biotech working to advance new therapies through the clinical development pipeline.
Why We Are Watching:
What draws attention to Terns is the expanding focus on metabolic disease treatments, one of the fastest-growing areas in biotechnology.
Obesity and related metabolic disorders affect hundreds of millions of people globally, and pharmaceutical companies are investing heavily to develop new therapies. Breakthrough treatments in this space can become significant commercial opportunities due to the size of the patient population.
What strengthens the positioning:
Pipeline exposure to obesity and metabolic disease therapeutics
Participation in a rapidly expanding metabolic drug development market
Potential for partnerships with larger pharmaceutical companies
Clinical programs aimed at large global patient populations
The risks are typical for early-stage biotech companies. Drug candidates must prove effective and safe in clinical trials, and regulatory approvals are never guaranteed. Development timelines can also extend over several years.
But structurally, demand for therapies addressing metabolic disorders continues to grow as global health trends shift. Companies with promising clinical programs often attract significant investor interest once clinical data begins to validate the science.
Terns Pharmaceuticals offers exposure to the innovation pipeline targeting metabolic disease, rather than an already established pharmaceutical product franchise.
Revenue:
Nebius Group N.V. (NBIS)
1 Year Chart:
Technical Levels To Watch: UNLOCK
Risk Considerations: UNLOCK
Potential Upside: UNLOCK
Market Cap: $28.5B
Company Info:
Nebius Group operates in the fast-growing world of AI infrastructure and cloud computing.
The company focuses on building and operating high-performance computing platforms designed specifically for artificial intelligence workloads. Its infrastructure supports companies that need massive processing power to train and run machine learning models.
The business primarily centers on:
Providing AI-focused cloud infrastructure
Operating large-scale GPU computing platforms
Supporting machine learning and data-intensive workloads
Building infrastructure for companies developing artificial intelligence applications
Nebius is not a traditional enterprise cloud provider. It focuses on compute-heavy AI workloads, where demand for specialized hardware and optimized infrastructure continues to expand.
Why We Are Watching:
What makes Nebius interesting is its positioning within the rapid buildout of AI computing infrastructure.
As artificial intelligence models become larger and more complex, companies require enormous amounts of processing power. That demand has triggered a global race to build GPU-powered data centers capable of supporting AI development and deployment.
Where the company fits:
Exposure to expanding AI infrastructure demand
Participation in the GPU cloud computing market
Positioned within the broader AI data center ecosystem
Potential growth as AI workloads scale globally
There are risks to consider. Building large-scale computing infrastructure requires significant capital, and competition from established cloud providers remains intense. Technology cycles in AI hardware can also evolve quickly.
Still, the long-term trajectory for AI computing continues upward. As more companies deploy large-scale models and data-intensive systems, demand for specialized compute platforms is likely to persist.
Nebius provides exposure to the hardware and infrastructure layer powering artificial intelligence, rather than the applications built on top of it.
Revenue:
DigitalOcean Holdings, Inc. (DOCN)
1 Year Chart:
Technical Levels To Watch: UNLOCK
Risk Considerations: UNLOCK
Potential Upside: UNLOCK
Market Cap: $6.3B
Company Info:
DigitalOcean is a cloud infrastructure provider built primarily for developers, startups, and small to mid-sized businesses.
Instead of competing directly with hyperscale providers like AWS or Azure in large enterprise environments, DigitalOcean focuses on simplicity and accessibility. Its platform offers computing, storage, networking, and database services designed to be easy for smaller teams to deploy and manage.
The company’s model centers around:
Delivering cloud compute, storage, and networking services
Serving developers and emerging digital businesses
Providing simplified, predictable cloud pricing models
Building tools that streamline application deployment
This is not a traditional enterprise cloud vendor. It targets companies that need reliable infrastructure without the complexity of large-scale cloud platforms.
Why We Are Watching:
Where DigitalOcean becomes interesting is its focus on the long tail of developer-led cloud adoption.
Thousands of startups and smaller software companies are constantly launching new applications, services, and online platforms. Many of them prefer cloud environments that are straightforward to use rather than highly complex enterprise ecosystems.
What supports the positioning:
A strong reputation among developer communities
Recurring revenue tied to cloud infrastructure usage
Exposure to growth in startup and SaaS formation
Platform tools that simplify cloud deployment and management
Competition remains a reality. Larger cloud providers dominate the industry and can compete aggressively on features and scale. Customer growth also depends on the health of the startup ecosystem.
Still, digital business creation continues globally, and developers remain at the center of that expansion. Infrastructure providers that simplify deployment and scaling can remain relevant even alongside much larger competitors.
DigitalOcean offers exposure to the developer-driven segment of cloud computing, rather than enterprise hyperscale cloud dominance.
Revenue:
Thank you for your time!
P.S. Just a quick reminder — the 25% discount on all Momentum plans ends this week (both monthly and yearly plans).
If you’ve been thinking about joining, this is a good week to take a look.
Stay tuned for our next free release every Monday!
Disclaimer: The stocks mentioned in this email do not represent the exact positions of Crown Trading, but rather ideas and opportunities we are currently monitoring. Just because a stock is featured here does not mean we own or are actively trading it. The buy levels are not recommendations. This is not financial advice, and neither myself nor Crown Trading is recommending that you buy or sell any securities. All information is for educational purposes only and should not be relied upon for investment decisions. Please do your own research before making any trades.